Equities

Telomir Pharmaceuticals Inc

TELO:NAQ

Telomir Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)6.30
  • Today's Change0.70 / 12.50%
  • Shares traded1.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of May 23 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Telomir Pharmaceuticals, Inc. is a United States-based company. The Company operates as pre-clinical-stage pharmaceutical company focused on developing TELOMIR-1 small molecule to lengthen the deoxyribonucleic acid’s (DNA) protective telomere caps to affect age reversal. It selectively affects the processes that drive the concentration and accumulation of iron and copper in the serum that affects diseases like hemochromatosis and cancer.

  • Revenue in USD (TTM)0.00
  • Net income in USD-18.84m
  • Incorporated2021
  • Employees1.00
  • Location
    Telomir Pharmaceuticals Inc900 West Platt Street, Suite 200TAMPA 33606United StatesUSA
  • Phone+1 (813) 864-2562
  • Websitehttps://telomirpharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Trevi Therapeutics Inc0.00-33.57m178.91m25.00--2.42-----0.338-0.3380.001.050.00----0.00-34.47-47.39-38.08-54.41------------0.0017------0.2984---2.81--
Atossa Therapeutics Inc0.00-29.69m183.61m10.00--2.14-----0.2359-0.23590.000.68330.00----0.00-28.65-29.97-29.84-32.55------------0.00-------11.62---33.90--
bluebird bio Inc21.73m-91.17m184.49m323.00--0.4661--8.49-0.7446-0.74460.21392.080.0383----67,263.16-16.08-33.02-21.50-37.14-10.0819.44-419.62-4,044.311.42--0.00---1.77-36.7152.62---26.66--
Alpha Tau Medical Ltd0.00-28.95m184.63m121.00--2.34-----0.4165-0.41650.001.130.00----0.00-26.50---28.08--------------0.0653------13.64------
Achieve Life Sciences Inc0.00-27.32m185.79m22.00--3.75-----1.29-1.290.001.440.00----0.00-60.15-86.31-109.37-119.59-----------9.330.2574------29.60---14.51--
Veru Inc13.48m-35.82m185.91m189.00--4.11--13.79-0.3465-0.34650.12670.30890.18981.423.8671,318.68-50.43-42.91-76.84-54.4134.1372.41-265.74-104.964.22--0.177---58.590.5394-10.84--67.39--
Telomir Pharmaceuticals Inc0.00-18.84m186.54m1.00--61.84-----0.6889-0.68890.000.1019------0.00-------------------0.89860.00-------1,430.39------
Fennec Pharmaceuticals Inc44.95m2.84m187.70m36.00187.8661.7866.004.180.03660.03661.620.11120.98781.157.52--6.25-73.437.37-84.3296.19--6.33-383.286.721.840.9087--1,284.50--32.34------
Zevra Therapeutics Inc28.01m-50.90m187.92m65.00--3.85--6.71-1.34-1.340.75131.170.2172--3.47430,876.90-39.48-32.11-47.94-39.8951.11---181.75-128.42----0.4929--170.26---72.00--69.75--
Galectin Therapeutics Inc0.00-44.78m189.55m14.00---------0.7373-0.73730.00-1.140.00----0.00-177.94-92.08-373.85-121.97-----------10.247.25-------15.26------
P3 Health Partners Inc1.35bn-67.27m189.67m400.00--0.4887--0.1402-0.5855-0.585511.861.231.57--11.403,381,965.00-21.31---90.11--1.590.1781-13.57-56.93---10.050.2368--20.6770.5878.61---11.20--
Omeros Corp0.00-179.09m190.64m198.00---------2.90-1.970.00-1.230.00----0.00-35.90-55.51-44.81-70.10-----------5.391.19------3.91---5.56--
Puma Biotechnology Inc226.63m15.38m192.47m185.0012.403.777.150.84930.32190.32194.741.061.1010.958.131,225,016.007.49-12.2111.65-20.5373.4478.786.78-11.791.382.570.6624--3.34-1.251,079,450.00--83.41--
Capricor Therapeutics Inc27.10m-24.31m193.10m101.00--10.40--7.13-0.8755-0.87550.95740.58340.5246--59.13268,299.50-47.07-54.12-122.20-75.13-----89.72-316.25----0.1548--886.8172.0223.20--45.27--
Lineage Cell Therapeutics Inc8.00m-23.66m194.49m75.00--2.69--24.30-0.1344-0.13440.04550.38360.0722--57.16106,706.70-21.32-19.53-24.82-22.5991.8889.13-295.30-370.88----0.0018---39.1612.3918.22---27.16--
Renovaro Inc0.00-53.93m194.71m11.00--1.15-----0.7661-0.76610.001.140.00----0.00-37.06-27.81-41.75-28.44-----------24.380.0405------65.02---0.1538--
Data as of May 23 2024. Currency figures normalised to Telomir Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

0.27%Per cent of shares held by top holders
HolderShares% Held
Suncoast Equity Management LLCas of 31 Mar 202424.39k0.08%
Citigroup Global Markets, Inc. (Investment Management)as of 31 Mar 202417.75k0.06%
Lido Advisors LLCas of 31 Mar 202415.00k0.05%
FNY Capital Management LPas of 31 Mar 202414.90k0.05%
Beaird Harris Wealth Management LLCas of 31 Mar 20244.67k0.02%
JPMorgan Securities LLC (Investment Management)as of 31 Mar 20242.61k0.01%
Arbor Point Advisors LLCas of 31 Mar 2024600.000.00%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.